Celyad Oncology S.A.
CYAD
Rank in Stocks
#29398
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Share Price
$0.16500743
Last synced: 2026-11-17
Market Cap
$7.39M
Change (1 day)
6.90%
Change (1 year)
-23.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Celyad Oncology S.A. (CYAD)
Category
Healthcare
Operating Margin for Celyad Oncology S.A. (CYAD)
Operating Margin as of November 2026 TTM: -68,728.57%
According to Celyad Oncology S.A.'s latest financial reports, its current operating margin (TTM) is -68,728.57%. At the end of 2025 the company had an operating margin of -34,200.00%.
Operating Margin history for Celyad Oncology S.A. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -68,728.57% | 100.96% |
| 2025 | -34,200.00% | 916.33% |
| 2024 | -3,365.05% | -67.61% |
| 2023 | -10,389.22% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -339,740.00% | -29.41% |
| 2019 | -481,316.67% | 39,179.61% |
| 2018 | -1,225.36% | -17.96% |
| 2017 | -1,493.67% | 483.97% |
| 2016 | -255.78% | -99.97% |
| 2015 | -989,066.67% | 8,685.28% |
| 2014 | -11,258.22% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | -2,668.52% | -92.09% |
| 2011 | -33,725.68% | 5,769.42% |
| 2010 | -574.60% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 33.87% | -100.00% |
US
|
|
| -116.04% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 29.35% | -100.00% |
NL
|
|
| 31.23% | -100.00% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Celyad Oncology S.A.'s operating margin
What is Celyad Oncology S.A.'s operating margin?
Celyad Oncology S.A.'s operating margin is -68,728.57%, as of Nov 2026.
What was Celyad Oncology S.A.'s operating margin in 2025?
In 2025, Celyad Oncology S.A.'s operating margin was -34,200.00%, compared with -3,365.05% in 2024.
How has Celyad Oncology S.A.'s operating margin changed since 2020?
From 2020 to 2025, Celyad Oncology S.A.'s operating margin was highest in 2022 (0.00%) and lowest in 2020 (-339,740.00%).
How does Celyad Oncology S.A.'s operating margin compare with similar companies?
Celyad Oncology S.A.'s operating margin (-68,728.57%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.